Jane Street’s Neumora Therapeutics NMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.46M Sell
747,665
-381,307
-34% -$988K ﹤0.01% 5699
2025
Q4
$2.02M Buy
1,128,972
+973,056
+624% +$2.13M ﹤0.01% 4786
2025
Q3
$284K Sell
155,916
-141,214
-48% -$228K ﹤0.01% 9014
2025
Q2
$218K Buy
297,130
+100,100
+51% +$75.8K ﹤0.01% 8401
2025
Q1
$197K Buy
197,030
+172,876
+716% +$296K ﹤0.01% 8464
2024
Q4
$256K Sell
24,154
-16,485
-41% -$198K ﹤0.01% 7991
2024
Q3
$537K Buy
40,639
+12,339
+44% +$144K ﹤0.01% 7066
2024
Q2
$278K Sell
28,300
-12,397
-30% -$128K ﹤0.01% 7918
2024
Q1
$560K Sell
40,697
-48,642
-54% -$786K ﹤0.01% 6461
2023
Q4
$1.52M Buy
+89,339
New +$1.1M ﹤0.01% 4795

Other funds holding NMRA

Jane Street's NMRA Position: Q1 2026 in Review

Jane Street reduced its Neumora Therapeutics (NMRA) stake by 34% in Q1 2026, selling an estimated $988K and leaving 747,665 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #5699.

Jane Street first reported a position in NMRA in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.02M in Q4 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Jane Street held 747,665 shares of Neumora Therapeutics worth $1.46M as of Q1 2026.
  • Jane Street sold 381,307 Neumora Therapeutics shares in Q1 2026, an estimated $988K.
  • Neumora Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5699 holding.
  • Jane Street first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Jane Street's Neumora Therapeutics position peaked at $2.02M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.